Why Immunotherapy Causes Side Effects: The Science Behind the Symptoms

The Double-Edged Sword of Immune Activation

Immunotherapy, particularly immunocellular therapy, has revolutionized oncology by harnessing the patient's own immune system to recognize and eliminate malignant cells. Unlike traditional chemotherapy, which directly poisons rapidly dividing cells, immunocellular therapy reinvigorates exhausted cytotoxic T lymphocytes, enabling them to target tumor-specific antigens with high specificity. The clinical success rate for immunotherapy varies significantly by cancer type; for instance, in advanced melanoma and non-small cell lung cancer, durable responses exceeding five years have been observed in approximately 20-30% of patients treated with checkpoint inhibitors in Hong Kong cancer centers. This remarkable achievement has shifted the paradigm from acute cytotoxic treatment to chronic immune management.

However, this powerful immune activation comes with a price. Because the immune system is not genetically engineered to attack only cancer cells with perfect precision, the enhanced activity often spills over into healthy tissues. These unintended inflammatory events are clinically classified as immune-related adverse events (irAEs). The fundamental paradox of immunotherapy is that its very mechanism of action—unleashing T-cell proliferation and cytokine release—inevitably creates a fertile ground for autoimmunity. The immune system, once released from its natural inhibitory brakes, cannot always distinguish between a foreign tumor and self-tissue. Understanding the science behind immunotherapy side effects is therefore not merely an academic exercise; it is essential for predicting toxicity, improving patient quality of life, and ultimately expanding the therapeutic window of these life-saving drugs.

The Immune System's Role in irAEs

Checkpoint Inhibitors: PD-1, PD-L1, and CTLA-4 Blockade

The most widely used immunotherapeutic agents are immune checkpoint inhibitors (ICIs). Under normal physiological conditions, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) act as immune 'brakes,' preventing overactivation that could lead to autoimmunity. CTLA-4 functions primarily in lymph nodes during the priming phase of T-cell activation, competing with CD28 for binding to B7 ligands on antigen-presenting cells. PD-1, in contrast, operates in peripheral tissues during the effector phase, binding to its ligands PD-L1 and PD-L2 expressed on tumor cells and stroma to induce T-cell exhaustion. By blocking these checkpoints with monoclonal antibodies—such as ipilimumab (anti-CTLA-4), nivolumab, and pembrolizumab (anti-PD-1)—clinicians effectively remove the brakes, allowing T-cells to proliferate aggressively and mount an attack against tumors.

How Blocking Checkpoints Leads to Autoimmune-Like Reactions

The problem arises because these same checkpoint pathways are crucial for maintaining peripheral tolerance. When PD-1 is blocked, T-cells that are weakly self-reactive but normally suppressed by the PD-1/PD-L1 axis become unleashed. These autoreactive clones can then infiltrate normal organs such as the colon, skin, liver, and endocrine glands. Furthermore, the blockade of CTLA-4 reduces the suppressive function of regulatory T-cells (Tregs), which are the immune system's dedicated peacekeepers. Without adequate Treg activity, effector T-cells proliferate uncontrollably and secrete pro-inflammatory cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). This cytokine storm creates a self-amplifying loop of inflammation, breaking down the barriers that normally protect healthy tissue from immune attack. Clinical data from Queen Mary Hospital in Hong Kong show that patients receiving combination ipilimumab and nivolumab have an incidence of grade 3-4 irAEs approaching 55%, compared to 10-20% for monotherapy, underscoring how removing multiple checkpoints exponentially increases the risk of autoimmune-like reactions.

T-cell Activation and Inflammation in Healthy Tissues

Beyond checkpoint blockade, the activated T-cells themselves cause direct tissue damage through several mechanisms. Cytotoxic CD8+ T-cells release perforin and granzyme B, which form pores in target cell membranes and induce apoptosis. In healthy organs, these same molecules destroy normal parenchymal cells. Additionally, activated CD4+ T-helper cells recruit macrophages and neutrophils, amplifying local inflammation. The resulting tissue damage releases intracellular antigens, which are then presented to additional T-cells, further broadening the autoimmune response—a phenomenon known as epitope spreading. This explains why irAEs can be unpredictable and can affect multiple organ systems simultaneously.

Organ-Specific Mechanisms

Skin: Dermatitis and Vitiligo

The skin is the most commonly affected organ in irAEs, with maculopapular rash occurring in up to 40% of patients on anti-PD-1 therapy. The mechanism involves activated T-cells recognizing melanocyte differentiation antigens, such as tyrosinase and MART-1, which are homologous to melanoma-associated antigens. When immunotherapy attacks these shared antigens, it produces vitiligo-like depigmentation—ironically, a positive prognostic marker in melanoma patients. Histologically, skin biopsies show a lichenoid interface dermatitis with CD8+ T-cell infiltrates at the dermal-epidermal junction. Pruritus and urticaria are driven by mast cell degranulation and histamine release triggered by Th2 cytokines. The severity ranges from mild, self-limiting rashes to severe Stevens-Johnson syndrome, though the latter is rare. In Hong Kong, dermatologists remain vigilant because Asian skin types may present with hyperpigmentation rather than obvious erythema, potentially delaying diagnosis.

Gut: Colitis

Immune-mediated colitis is the second most common irAE, occurring in up to 30% of patients on anti-CTLA-4 therapy and 10-20% on anti-PD-1. The pathophysiology involves T-cell infiltration into the colonic lamina propria, with depletion of Tregs leading to loss of gut tolerance. Activated T-cells produce high levels of IL-17, recruiting neutrophils and causing crypt abscesses. Endoscopically, the colon appears edematous with mucosal friability, resembling inflammatory bowel disease. Patients present with watery diarrhea, abdominal cramping, and occasionally bloody stools. The microbiome plays a crucial role: Hong Kong studies have shown that patients with a higher baseline abundance of Bacteroides species have a lower risk of severe colitis, likely because these bacteria promote local Treg differentiation. Diarrhea must be distinguished from infectious causes, particularly Clostridium difficile and cytomegalovirus, which can complicate immunosuppressive treatment.

Endocrine Glands: Thyroiditis and Hypophysitis

Endocrine irAEs are unique because they are often permanent, requiring lifelong hormone replacement. Thyroid dysfunction, most commonly thyrotoxicosis followed by hypothyroidism, occurs in roughly 10-15% of patients on anti-PD-1 therapy. The mechanism is a destructive thyroiditis: activated T-cells infiltrate the thyroid gland, causing follicular cell destruction and release of preformed thyroid hormone into the circulation (thyrotoxic phase), followed by glandular fibrosis and hormone deficiency (hypothyroid phase). In Hong Kong, where iodine intake is adequate, these thyroid autoantibodies are frequently negative, distinguishing irAE thyroiditis from classic Graves' disease. Hypophysitis is more strongly associated with anti-CTLA-4 antibodies, with incidence rates of 3-5%. Immune infiltration of the pituitary gland compresses hormone-producing cells, leading to secondary adrenal insufficiency, central hypothyroidism, and hypogonadism. The presentation is insidious—fatigue, headache, and hyponatremia—and can be mistaken for cancer progression, highlighting the need for careful endocrine surveillance.

Liver: Hepatitis

Immune-mediated hepatitis presents with asymptomatic transaminitis in most cases, but can progress to acute liver failure in less than 1% of patients. The underlying mechanism is a CD8+ T-cell-mediated attack on hepatocytes and bile duct epithelial cells. Anti-CTLA-4 agents more frequently cause a granulomatous pattern of inflammation, while anti-PD-1 agents cause a lobular hepatitis with interface activity. Bilirubin elevation is a more concerning sign than simple transaminase elevation, as it suggests cholestatic injury or massive hepatic necrosis. In Hong Kong, where hepatitis B virus (HBV) carriage is endemic, oncologists face the additional challenge of differentiating irAE hepatitis from HBV reactivation. All patients must undergo baseline HBV screening, and those with prior infection should receive prophylactic antiviral therapy before starting immunotherapy.

Lungs: Pneumonitis

Pneumonitis is less common than skin or gut toxicity but is among the most feared irAEs because it can be fatal. It occurs in 3-5% of patients receiving anti-PD-1/PD-L1 therapy, with higher rates in patients with pre-existing lung disease or prior thoracic radiation. The mechanism involves activated T-cells infiltrating the lung interstitium and alveolar spaces, producing a hypersensitivity pneumonitis pattern. Activated macrophages release profibrotic cytokines like TGF-β, which can lead to organizing pneumonia or interstitial lung disease. Clinically, patients develop a dry cough, dyspnea, and hypoxemia. Imaging typically shows ground-glass opacities, consolidations, or a cryptogenic organizing pneumonia pattern. In Hong Kong's light-polluted urban environment, distinguishing pneumonitis from new tumor progression, radiation pneumonitis, or infection requires multidisciplinary evaluation and often bronchoscopy with bronchoalveolar lavage.

Factors Influencing irAE Development

Type of Immunotherapy Agent

Different classes of immunotherapy drugs have distinct toxicity profiles. Anti-CTLA-4 antibodies (ipilimumab) are more likely to cause colitis, hypophysitis, and hepatotoxicity, while anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab) more commonly cause pneumonitis, thyroiditis, and arthralgias. Combination ICI therapy significantly increases the incidence and severity of all irAEs. Newer modalities like bispecific T-cell engagers and CAR-T-cell therapy—forms of immunocellular therapy—carry risks of cytokine release syndrome and neurotoxicity, which are distinct from classical irAEs.

Combination Therapies

Combining immunotherapy with chemotherapy, targeted therapy, or radiation increases irAE risk. Vascular endothelial growth factor (VEGF) inhibitors, when combined with ICIs, can increase the risk of proteinuria and bleeding. Radiation therapy releases neoantigens that can prime a systemic immune response, known as the abscopal effect, but also amplifies local inflammation in the irradiated field. The success rate for immunotherapy decreases when patients require dose reductions or treatment delays due to toxicity, making management of combinatory effects critical.

Patient's Underlying Autoimmune Conditions

Patients with pre-existing autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease) have traditionally been excluded from clinical trials. However, real-world evidence suggests they can safely receive ICIs, albeit with higher irAE rates—particularly exacerbations of their underlying condition. Hong Kong real-world data from the Prince of Wales Hospital shows that up to 60% of patients with pre-existing autoimmune disease experience disease flare, though most are grade 1-2 and manageable without immunotherapy discontinuation.

Genetic Predispositions

Genetic factors significantly influence irAE susceptibility. Certain HLA haplotypes, such as HLA-DRB1*03:01, are associated with increased risk of severe colitis and pneumonitis. Polymorphisms in cytokine genes, including IL-17 and TNF-α, can modulate the inflammatory response. Pharmacogenomic studies are ongoing to identify predictive biomarkers that could personalize treatment selection and monitoring strategies.

Management Based on Mechanism: Immunosuppression

Role of Corticosteroids and Other Immunosuppressants

Corticosteroids are the first-line treatment for moderate-to-severe irAEs. They work by binding to glucocorticoid receptors on immune cells, suppressing the transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reducing T-cell proliferation, and promoting apoptosis of activated lymphocytes. The standard regimen is prednisolone 1-2 mg/kg/day, with a taper over 4-6 weeks. For steroid-refractory cases—occurring in 10-20% of severe irAEs—second-line agents are required. Infliximab, a TNF-α inhibitor, is highly effective for steroid-refractory colitis and can produce clinical response within 24-48 hours. Mycophenolate mofetil is preferred for hepatitis due to its liver-specific metabolism. Cyclophosphamide and anti-thymocyte globulin are reserved for life-threatening pneumonitis or myocarditis.

Tailoring Treatment to the Specific irAE

Management must be tailored to both the organ system and the severity grade. For grade 1 irAEs, immunotherapy can usually be continued under close observation. Grade 2 events often require temporary treatment interruption and oral corticosteroids. Grade 3-4 events demand immediate hospitalization, high-dose intravenous corticosteroids, and permanent discontinuation of the offending agent. Importantly, hormone replacement therapy (thyroxine, hydrocortisone, desmopressin) is necessary for permanent endocrine damage, since immunosuppression cannot reverse gland fibrosis. The guiding principle is to suppress the immune response just enough to control toxicity without completely negating the anti-tumor effect. Paradoxically, several studies—including data from the Hong Kong Cancer Registry—have shown that patients who develop mild-to-moderate irAEs have better overall survival, suggesting that some toxicity may be a surrogate marker for a more robust immune activation against the tumor.

Balancing Efficacy and Safety Through Understanding

Immunotherapy has fundamentally changed the landscape of oncology, offering durable remissions for patients with previously incurable cancers. However, the double-edged nature of immune activation demands that clinicians understand the basic science underpinning immunotherapy side effects. By recognizing organ-specific mechanisms—from checkpoint blockade in the lymph node to T-cell infiltration in the thyroid—physicians can anticipate, diagnose, and treat toxicities proactively. The clinical success rate for immunotherapy will continue to improve not only through the development of more selective agents but through better management of its unavoidable consequences. As we move toward the next generation of immunocellular therapy, with engineered T-cells and bispecific antibodies, the principles remain the same: the immune system must be empowered to fight cancer without being allowed to turn against the host. It is this delicate balance—between efficacy and autoimmunity—that defines the future of immunotherapy.